"シオノギ製薬" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonShionogi Selected as a “DX Stock 2026”｜ 塩野義製薬 - Shionogi Inc.
Shionogi Selected as a “DX Stock 2026”｜ 塩野義製薬 Shionogi Inc.
Shionogi Co: Shionogi China Has Received Approval From NMPA Of China For Naldemedine, A Treatment...
Shionogi weighs future of FXS drug after double Phase III miss - Clinical Trials Arena
Shionogi weighs future of FXS drug after double Phase III miss Clinical Trials Arena
Shionogi Pill Prevents Covid in Household Exposure Study - Bloomberg.com
Shionogi Pill Prevents Covid in Household Exposure Study Bloomberg.com
Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture S...
【CM】シオノギ製薬 新セデス錠 2016 山本美月 Bt Consumer Brand Relaunch (VhYl2QJmyI) - Mshale
【CM】シオノギ製薬 新セデス錠 2016 山本美月 Bt Consumer Brand Relaunch (VhYl2QJmyI) Mshale
Shionogi Secures US Contract to Expand Antibiotic Manufacturing and Biothreat Preparedness - Cont...
Shionogi Secures US Contract to Expand Antibiotic Manufacturing and Biothreat Preparedness Contagion Live
Shionogi secures BARDA contract for cefiderocol for resistant infections, bioterror threats - CIDRAP
Shionogi secures BARDA contract for cefiderocol for resistant infections, bioterror threats CIDRAP
Shionogi's (TSE:4507) Earnings Are Of Questionable Quality - simplywall.st
Shionogi's (TSE:4507) Earnings Are Of Questionable Quality simplywall.st
Fierce Pharma Asia—Takeda-Denali split-up; Merck, Zhifei's revised deal; Shionogi's made-in-US pl...
Fierce Pharma Asia—Takeda-Denali split-up; Merck, Zhifei's revised deal; Shionogi's made-in-US plan Fierce Pharma
Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream - Fierce Biotech
Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream Fierce Biotech
Shionogi secures $482m BARDA contract to tackle AMR crisis - Pharmaceutical Technology
Shionogi secures $482m BARDA contract to tackle AMR crisis Pharmaceutical Technology
Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness...
Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats Pharmaceutical Executive
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID...
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure Yahoo Finance
Shionogi enrols first patients in Esprit trial for Pompe disease - Clinical Trials Arena
Shionogi enrols first patients in Esprit trial for Pompe disease Clinical Trials Arena
Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi - PR Ne...
Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi PR Newswire
Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant - Fierce Pharma
Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant Fierce Pharma
Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava - Pharmaceutical Executive
Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava Pharmaceutical Executive
Shionogi & Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:SGIOY) 2026-05-16 - ...
Shionogi & Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:SGIOY) 2026-05-16 Seeking Alpha
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) - Business Wire
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) Business Wire
The Shionogi & Co., Ltd. (TSE:4507) Annual Results Are Out And Analysts Have Published New Foreca...
The Shionogi & Co., Ltd. (TSE:4507) Annual Results Are Out And Analysts Have Published New Forecasts simplywall.st
Shionogi starts phase 2 clinical trial for Pompe Disease - PMLiVE
Shionogi starts phase 2 clinical trial for Pompe Disease PMLiVE
The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the N...
The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the Next Generation Shionogi Inc.
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s ...
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science Pharmaceutical Executive
Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership - Yahoo Finance
Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership Yahoo Finance
Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up - Pharmaceutical Technology
Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up Pharmaceutical Technology
Shionogi pill prevents COVID-19 in household exposure study - The Japan Times
Shionogi pill prevents COVID-19 in household exposure study The Japan Times
Shionogi (TSE:4507): Evaluating Valuation After a Strong Year-to-Date Share Price Gain - Yahoo Fi...
Shionogi (TSE:4507): Evaluating Valuation After a Strong Year-to-Date Share Price Gain Yahoo Finance
Shionogi moves to acquire global rights to Radicava for ALS - ALS News Today
Shionogi moves to acquire global rights to Radicava for ALS ALS News Today
Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer - Pharmaceutical Executive
Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer Pharmaceutical Executive
Shionogi & Co: Record revenue and profit growth fueled by M&A, royalties, and new product launche...
Shionogi & Co: Record revenue and profit growth fueled by M&A, royalties, and new product launches TradingView
Japan's Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits - Yahoo Finance
Japan's Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits Yahoo Finance
ALS med Radicava to change hands as Shionogi inks $2.5B buyout - Fierce Pharma
ALS med Radicava to change hands as Shionogi inks $2.5B buyout Fierce Pharma
Shionogi Expects FY Japan Prescription Drugs Revenue at Y178.6B Vs Y123.5B Previous FY - Moomoo
Shionogi Expects FY Japan Prescription Drugs Revenue at Y178.6B Vs Y123.5B Previous FY Moomoo
Shionogi to Present RADICAVA® (edaravone) ORS and Digital Health Analyses in ALS at AAN 2026 - Ya...
Shionogi to Present RADICAVA® (edaravone) ORS and Digital Health Analyses in ALS at AAN 2026 Yahoo Finance
Pharma Pulse: Shionogi’s $2.5B Radicava Acquisition and the Industry Monitors U.S.-Iran Conflict ...
Pharma Pulse: Shionogi’s $2.5B Radicava Acquisition and the Industry Monitors U.S.-Iran Conflict for Supply Disruptions Pharmaceutical Commerce
[Press release] GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding - Europ...
[Press release] GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding European AIDS Treatment Group
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance Nati...
Pfizer exits ViiV, selling stake to Shionogi in $2.1B deal - FirstWord Pharma
Pfizer exits ViiV, selling stake to Shionogi in $2.1B deal FirstWord Pharma
Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADI...
Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADICAVA Cleary Gottlieb
Shionogi completes $2.5B deal for ALS drug Radicava rights (updated) - NJBIZ
Shionogi completes $2.5B deal for ALS drug Radicava rights (updated) NJBIZ
Shionogi Increasing Stake in ViiV Healthcare for $2.1 Bn; Pfizer Exits the HIV JV - DCAT Value Ch...
Shionogi Increasing Stake in ViiV Healthcare for $2.1 Bn; Pfizer Exits the HIV JV DCAT Value Chain Insights
Shionogi’s BARDA contract; Scinai finalizes CDMO unit setup - Endpoints News
Shionogi’s BARDA contract; Scinai finalizes CDMO unit setup Endpoints News
Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma...
Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business - Fierc...
Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business Fierce Pharma
Shionogi Outlines FY2025 Results, FY2026 Outlook and 2030 Strategy - The Globe and Mail
Shionogi Outlines FY2025 Results, FY2026 Outlook and 2030 Strategy The Globe and Mail
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-O...
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease Business Wire
Shionogi Gets $119m Fetroja Purchase Commitment From BARDA - Citeline News & Insights
Shionogi Gets $119m Fetroja Purchase Commitment From BARDA Citeline News & Insights
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - Reuters
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake Reuters
Can Shionogi’s Rally Continue After Key Drug Approval in 2025? - Yahoo Finance
Can Shionogi’s Rally Continue After Key Drug Approval in 2025? Yahoo Finance
Shionogi 4Q Net Profit Beat Y38.3B Expected in Poll of Analysts by Visible Alpha - Moomoo
Shionogi 4Q Net Profit Beat Y38.3B Expected in Poll of Analysts by Visible Alpha Moomoo
Shionogi buys out Apnimed's stake in sleep-focused joint venture for $100M - FirstWord Pharma
Shionogi buys out Apnimed's stake in sleep-focused joint venture for $100M FirstWord Pharma
Shionogi to acquire ALS medications from Tanabe - The Pharma Letter
Shionogi to acquire ALS medications from Tanabe The Pharma Letter
Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance - Fierce Pharma
Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance Fierce Pharma
Yomiuri: Shionogi Inks Contract with U.S. Govt For Antibiotics Production - MarketWatch
Yomiuri: Shionogi Inks Contract with U.S. Govt For Antibiotics Production MarketWatch
Shionogi MDD drug Zurzuvae launched in Japan - The Pharma Letter
Shionogi MDD drug Zurzuvae launched in Japan The Pharma Letter
GSK, Pfizer and Shionogi finalize changes to ViiV Healthcare ownership - Investing.com
GSK, Pfizer and Shionogi finalize changes to ViiV Healthcare ownership Investing.com
Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused ...
Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company Fierce Pharma
Shionogi's Ensitrelvir cuts symptomatic COVID-19 risk to one-third, NEJM reports - 동아사이언스
Shionogi's Ensitrelvir cuts symptomatic COVID-19 risk to one-third, NEJM reports 동아사이언스
Shionogi to buy Jersey City pharma for $2.5B - NJBIZ
FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP - Infectious Disease Special Edition
FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP Infectious Disease Special Edition
Shionogi: Key Advice on Migrating to Vault CRM - Veeva
Shionogi makes investment in Japanese startup Restore Vision to develop visual restoration gene t...
Shionogi makes investment in Japanese startup Restore Vision to develop visual restoration gene therapy BioSpectrum Asia
Shionogi inks hearing loss deal with Salubritas Therapeutics - The Pharma Letter
Shionogi inks hearing loss deal with Salubritas Therapeutics The Pharma Letter
FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention - C...
FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention Contagion Live
Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Custom...
Shionogi & Co Ltd - To Acquire 50% Stake In Shionogi‑Apnimed Sleep Science For $100 Mln From Apni...
Shionogi & Co Ltd - To Acquire 50% Stake In Shionogi‑Apnimed Sleep Science For $100 Mln From Apnimed Inc TradingView
Shionogi Expands Rare Disease Portfolio With $2.5bn Radicava Buy From Tanabe - Citeline News & In...
Shionogi Expands Rare Disease Portfolio With $2.5bn Radicava Buy From Tanabe Citeline News & Insights
We’re reading about the first approved GLP-1 pill, deal-hungry Ipsen, and more - statnews.com
We’re reading about the first approved GLP-1 pill, deal-hungry Ipsen, and more statnews.com
Analysis of depressive symptom trajectory patterns with zuranolone: Time-series clustering of Jap...
Analysis of depressive symptom trajectory patterns with zuranolone: Time-series clustering of Japanese Phase 2 and Phase 3 trial data Wiley Online Library
Shionogi expands stake in ViiV Healthcare following Pfizer’s exit, GSK retains majority share - B...
Shionogi expands stake in ViiV Healthcare following Pfizer’s exit, GSK retains majority share BioXconomy
Pfizer sells ViiV stake to Shionogi - The Pharma Letter
Pfizer sells ViiV stake to Shionogi The Pharma Letter
Japan's Shionogi joins World Economic Forum and signs Davos Compact on Antimicrobial Resistance -...
Japan's Shionogi joins World Economic Forum and signs Davos Compact on Antimicrobial Resistance BioSpectrum Asia
Shionogi & Co., Ltd. Provides Year-End Dividend Guidance for the Year Ending March 31, 2027 - mar...
Shionogi & Co., Ltd. Provides Year-End Dividend Guidance for the Year Ending March 31, 2027 marketscreener.com
Pfizer to depart GSK’s ViiV as Shionogi doubles its stake - Endpoints News
Pfizer to depart GSK’s ViiV as Shionogi doubles its stake Endpoints News
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 F...
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure Business Wire
Shionogi lifts profit outlook on HIV royalties and overseas growth - The Japan Times
Shionogi lifts profit outlook on HIV royalties and overseas growth The Japan Times
Shionogi & Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026 - marketscre...
Shionogi & Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026 marketscreener.com
Shionogi: $2.5 Billion Acquisition Of RADICAVA Establishes Rare Disease Platform - Pulse 2.0
Shionogi: $2.5 Billion Acquisition Of RADICAVA Establishes Rare Disease Platform Pulse 2.0
Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs - Bloomberg.com
Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs Bloomberg.com
Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge - JAPAN Forward
Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge JAPAN Forward
Shionogi expands rare disease presence with acquisition of global rights to Tanabe's RADICAVA for...
Shionogi expands rare disease presence with acquisition of global rights to Tanabe's RADICAVA for $2.5 B BioSpectrum Asia
GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare - BioSpectrum Asia
GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare BioSpectrum Asia
Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners - Imperial College...
Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners Imperial College Healthcare NHS Trust
Japanese pharma’s Florham Park-based unit receives U.S. government contract to combat drug-resist...
Pfizer Pockets $1.9B by Offloading Stake in HIV Drugs Company Majority Owned by GSK - MedCity News
Pfizer Pockets $1.9B by Offloading Stake in HIV Drugs Company Majority Owned by GSK MedCity News
Drugmaker known for ALS medication to be acquired by Japanese company in $2.5B deal - NJ.com
Drugmaker known for ALS medication to be acquired by Japanese company in $2.5B deal NJ.com
GSK and Shionogi Restructure Stake in ViiV Healthcare - GuruFocus
GSK and Shionogi Restructure Stake in ViiV Healthcare GuruFocus
Shionogi & Co Ltd stock (JP3347200002): FDA update keeps U.S. investors focused - AD HOC NEWS
Shionogi & Co Ltd stock (JP3347200002): FDA update keeps U.S. investors focused AD HOC NEWS
Drugmakers announce encouraging new antibiotic data at IDWeek - CIDRAP
Drugmakers announce encouraging new antibiotic data at IDWeek CIDRAP
Shionogi strikes research and option deal with BioVersys for antibacterial assets - FirstWord Pharma
Shionogi strikes research and option deal with BioVersys for antibacterial assets FirstWord Pharma
GSK, Pfizer and Shionogi agree on ViiV Healthcare shareholding changes By Investing.com - Investi...
GSK, Pfizer and Shionogi agree on ViiV Healthcare shareholding changes By Investing.com Investing.com Nigeria
〘懐かCM〙2003年 シオノギ製薬『セデス』瀬戸朝香 ／ ロッテ『雪見だいふく』安西ひろこ＆ボブ・サップ...
〘懐かCM〙2003年 シオノギ製薬『セデス』瀬戸朝香 ／ ロッテ『雪見だいふく』安西ひろこ＆ボブ・サップ Ryan Poehling (RQZwcqL6iW) Mshale
Exploring New Frontiers In The Fight Against Malaria - Health Policy Watch
Exploring New Frontiers In The Fight Against Malaria Health Policy Watch
Gareth Morgan Named President of Qpex Biopharma, Inc. - Business Wire
Gareth Morgan Named President of Qpex Biopharma, Inc. Business Wire
Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program - Fierce Biotech
Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program Fierce Biotech
New antiviral application for COVID-19 preventive drug submitted to FDA - CIDRAP
New antiviral application for COVID-19 preventive drug submitted to FDA CIDRAP
BioVersys and Shionogi agree to develop ansamycin leads - Pharmaceutical Technology
BioVersys and Shionogi agree to develop ansamycin leads Pharmaceutical Technology
Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug - Bloomberg Law News
Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug Bloomberg Law News
Shionogi puts up to $600m behind BioVersys antibiotics - pharmaphorum
Shionogi puts up to $600m behind BioVersys antibiotics pharmaphorum